Literature DB >> 10960497

Galactose breath testing distinguishes variant and severe galactose-1-phosphate uridyltransferase genotypes.

G T Berry1, R H Singh, A T Mazur, N Guerrero, M J Kennedy, J Chen, R Reynolds, M J Palmieri, P D Klein, S Segal, L J Elsas.   

Abstract

A galactose breath test that quantitates [1-(13)C]galactose conversion to 13CO2 provides information on the whole body galactose oxidative capacity. As there is little information on the relationship between whole body oxidation and the genotype in patients with galactosemia, we measured the 13CO2 excretion for 2 h after administration of [1-(13)C]galactose in 37 patients (3-48 y old) with galactose-1-phosphate uridyltransferase (GALT) deficiency and 20 control subjects (3-37 y old). Eleven patients with the common Q188R/Q188R genotype and no detectable erythrocyte GALT activity eliminated <2% of a bolus of [1-(13)C]galactose as 13CO2 compared with 8.47 to 28.23% in controls. This defines a severe metabolic phenotype. Seven patients with one Q188R allele and a second mutant allele such as L195P, E308K, V151A, M142K, or Q344K and one patient with a K285N/unknown genotype also released <2% as 13CO2 in 2 h. The presence of N314D or S135L as the second mutant allele does not impair total body galactose oxidation, as individuals with the GALT genotype of Q188R/N314D, K285N/N314D, and Q188R/S135L had normal 2-h galactose breath tests. Subjects with S135L/S135L, N314D/N314D, S135L/deltaT2359 as well as other rarer genotypes such as R258C/Y209C, E203K/IVSC-N314D, K285N/T138M, Q188R/D113N, S135L/F171S, R148W/N314D, and IVSC-N314D/N314D oxidized galactose comparable to controls. The dissociation of residual erythrocyte GALT activity and whole body galactose oxidative capacity is exemplified by blacks with a S135L/S135L genotype and absent erythrocyte GALT activity. An oral 2-h [1-(13)C]galactose breath test distinguishes severe and variant GALT genotypes and enables delineation of the extent of impaired galactose metabolism in an array of patients who possess diverse GALT mutations. It may prove to be useful in establishing whether a patient is capable of manifesting disease similar to patients with a Q188R/Q188R genotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960497     DOI: 10.1203/00006450-200009000-00010

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Introduction to the Maastricht workshop: lessons from the past and new directions in galactosemia.

Authors:  Gerard T Berry; Louis J Elsas
Journal:  J Inherit Metab Dis       Date:  2010-11-30       Impact factor: 4.982

2.  Oxidation of galactose by galactose-1-phosphate uridyltransferase-deficient lymphoblasts.

Authors:  C Yager; J Gibson; B States; L J Elsas; S Segal
Journal:  J Inherit Metab Dis       Date:  2001-08       Impact factor: 4.982

3.  Negative screening tests in classical galactosaemia caused by S135L homozygosity.

Authors:  E Crushell; J Chukwu; P Mayne; J Blatny; E P Treacy
Journal:  J Inherit Metab Dis       Date:  2009-05-08       Impact factor: 4.982

4.  Galactose oxidation using (13)C in healthy and galactosemic children.

Authors:  D R Resende-Campanholi; G Porta; E Ferrioli; K Pfrimer; L A Del Ciampo; J S Camelo Junior
Journal:  Braz J Med Biol Res       Date:  2015-01-20       Impact factor: 2.590

5.  The 1-13 C galactose breath test in GALT deficient patients distinguishes NBS detected variant patients but does not predict outcome in classical phenotypes.

Authors:  Mendy M Welsink-Karssies; Dewi van Harskamp; Sacha Ferdinandusse; Carla E M Hollak; Hidde H Huidekoper; Mirian C H Janssen; E Marleen Kemper; Janneke G Langendonk; M Estela Rubio-Gozalbo; Maaike C de Vries; Frits A Wijburg; Henk Schierbeek; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2020-01-22       Impact factor: 4.982

6.  Arginine does not rescue p.Q188R mutation deleterious effect in classic galactosemia.

Authors:  Minela Haskovic; Britt Derks; Liesbeth van der Ploeg; Jorn Trommelen; Jean Nyakayiru; Luc J C van Loon; Sabrina Mackinnon; Wyatt W Yue; Roy W A Peake; Li Zha; Didem Demirbas; Wanshu Qi; Xiaoping Huang; Gerard T Berry; Jelle Achten; Jörgen Bierau; M Estela Rubio-Gozalbo; Ana I Coelho
Journal:  Orphanet J Rare Dis       Date:  2018-11-26       Impact factor: 4.123

7.  [13C]-galactose breath test in a patient with galactokinase deficiency and spastic diparesis.

Authors:  Can Ficicioglu; Didem Demirbas; Britt Derks; G Shashidhar Pai; David J Timson; Maria Estela Rubio-Gozalbo; Gerard T Berry
Journal:  JIMD Rep       Date:  2021-02-03

8.  The clinical and molecular spectrum of galactosemia in patients from the Cape Town region of South Africa.

Authors:  Howard Henderson; Felicity Leisegang; Ruth Brown; Brian Eley
Journal:  BMC Pediatr       Date:  2002-09-02       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.